Nuclide Therapeutics Secures £5 Million Milestone-Based Investment to Advance Precision Radiopharmaceuticals for Therapy-Resistant Cancers. 

London, UK – 22nd September 2025

Nuclide Therapeutics Ltd, a pioneering biotech company and King’s College London spin-out focused on developing targeted radiopharmaceuticals for therapy-resistant cancers, is pleased to announce the successful closure of a £5 million milestone-based first investment round, funded by Marathon Beteiligungs AG. Nuclide received the largest pre-money valuation of any King’s College London spin-out to date.

The funding will support the continued development of Nuclide’s proprietary product family of ALDH1A1-targeted radiotheranostics, which are radioactive drugs designed to identify and eliminate cancer cells that have evaded conventional therapies. With a pipeline already demonstrating exceptional preclinical data in lung and ovarian cancers, the investment will enable Nuclide to progress its lead candidates into first-in-human trials, expand into additional cancers, and accelerate the development of other assets in its discovery pipeline.

Muhammet Tanc PhD, Co-Founder, and CEO of Nuclide Therapeutics, commented:

“The launch of Nuclide Therapeutics marks a bold step forward in our mission to give therapy-resistant cancer patients an effective treatment option. Closing our funding round with the support of Marathon Beteiligungs AG gives us not just capital, but a true partner who shares our vision. Together, we are building a company focused on scientific excellence, translational impact, and improving the lives of patients who need it most.”

The investment is structured around defined R&D and regulatory milestones, providing NTx with both flexibility and strategic alignment as it moves toward Investigational New Drug (IND)-enabling studies.

Dr. Andreas Kluge, CEO of Marathon Beteiligungs AG, explains:

“Having known the market for years, we always rely on convincing approaches and are delighted to offer talented teams such as those at Nuclide more opportunities to develop their ideas.”

“Our integrated investment approach not only includes the provision of financial resources, but also building a close and, above all, fair partnership in the economic development of the company”, adds Matthias Untisz, CFO of Marathon Beteiligungs AG.

Nicolas Huber, Interim Director of King’s Innovation Catalyst, said: “We are very excited by the significant funding secured by the first spin-out from Prof. Witney's lab. This is a strong vote of confidence in King's depth of scientific and translational expertise in radiopharmaceuticals, including theranostics. The team and founding investor are world-class, and we are looking forward to Nuclide progressing their lead candidates for untreatable tumours, with significant potential impact for the lives of cancer patients worldwide”.

Ends

About Nuclide Therapeutics Ltd

Nuclide Therapeutics was born out of cutting-edge research at the Witney Lab in the School of Biomedical Engineering & Imaging Sciences at King’s College London, where the founding team set out to tackle one of the biggest challenges in oncology: how to detect and treat therapy-resistant cancers. Initially supported through >£4.5 million in grant funding from the Wellcome Trust, Nuclide Therapeutics is advancing a new generation of radiotheranostics designed to transform cancer care for patients who have exhausted standard treatment options.

About Marathon Beteiligungs AG

Marathon Beteiligungs AG is a German investment company that invests in promising teams and ideas in the field of radiopharmaceuticals. It supports visionary, high-quality projects that fit in with the experience of the group, which has been active in radiopharmaceuticals for decades.